Drug Trial Radar · NCT01519674
Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin
Last checked: Nov 20, 2026Latest source record: Feb 24, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
582
Actual
Start
Jun 2012
Primary completion
Oct 2013
Study completion Oct 2013
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jan 27, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in Asia, Europe, Oceania and South America. The aim of this clinical trial is to generate data demonstrating how to intensify diabetes treatment using BIAsp 30 (biphasic insulin aspart 30) by adding or substituting BIAsp 30 to sitagliptin in various regimens for type 2 patients inadequately controlled on sitagliptin and metformin (with or without other oral anti-diabetic drugs (OADs)). The trial is conducted as a phase 4 trial in the majority of the participating countries. However, in some countries the trial is conducted as phase 3b.
Conditions
- Diabetes
- Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart 30Drug
BIAsp 30 will be injected subcutaneously (under the skin) twice daily. Individually adjusted dose.
biphasic insulin aspart 30Drug
BIAsp 30 will be injected subcutaneously (under the skin) once daily. Individually adjusted dose.
sitagliptinDrug
Subjects will continue on their pre-trial sitagliptin treatment.
metforminDrug
Subjects will continue on their pre-trial metformin treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in HbA1c (Glycosylated Haemoglobin)Time frame: Week 0 to Week 24
Locations
69 sites in 10 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Buenos Aires, Argentina
Novo Nordisk Investigational Site
Buenos Aires, Argentina
Novo Nordisk Investigational Site
Caba, Argentina
Novo Nordisk Investigational Site
Caba, Argentina
Novo Nordisk Investigational Site
Mar del Plata, Argentina
Novo Nordisk Investigational Site
Morón, Argentina
Novo Nordisk Investigational Site
Broadmeadow, New South Wales, Australia
Novo Nordisk Investigational Site
Coffs Harbour, New South Wales, Australia
Novo Nordisk Investigational Site
Brasília, Brazil
Novo Nordisk Investigational Site
Curitiba, Brazil
Novo Nordisk Investigational Site
Fortaleza, Brazil
Novo Nordisk Investigational Site
Porto Alegre, Brazil
Novo Nordisk Investigational Site
São Paulo, São Paulo, Brazil
Novo Nordisk Investigational Site
Alexandroupoli, Greece
Novo Nordisk Investigational Site
Athens, Greece
Novo Nordisk Investigational Site
Athens, Greece
Novo Nordisk Investigational Site
Thessaloniki, Greece
Novo Nordisk Investigational Site
Thessaloniki, Greece
Novo Nordisk Investigational Site
Thessaloniki, Greece
Novo Nordisk Investigational Site
Hyderabad, Andhra Pradesh, India
Novo Nordisk Investigational Site
Hyderabad, Andhra Pradesh, India
Novo Nordisk Investigational Site
Hyderabad, Andhra Pradesh, India
Novo Nordisk Investigational Site
Visakhapatnam, Andhra Pradesh, India
Novo Nordisk Investigational Site
Ahmedabad, Gujarat, India
Novo Nordisk Investigational Site
Ahmedabad, Gujarat, India
Novo Nordisk Investigational Site
Bangalore, Karnataka, India
Novo Nordisk Investigational Site
Bangalore, Karnataka, India
Novo Nordisk Investigational Site
Bangalore, Karnataka, India
Novo Nordisk Investigational Site
Bangalore, Karnataka, India
Novo Nordisk Investigational Site
Calicut, Kerala, India
Novo Nordisk Investigational Site
Trivandrum, Kerala, India
Novo Nordisk Investigational Site
Nagpur, Maharashtra, India
Novo Nordisk Investigational Site
New Delhi, New Delhi, India
Novo Nordisk Investigational Site
Amritsar, Punjab, India
Novo Nordisk Investigational Site
Chennai, Tamil Nadu, India
Novo Nordisk Investigational Site
Chennai, Tamil Nadu, India
Novo Nordisk Investigational Site
Chennai, Tamil Nadu, India
Novo Nordisk Investigational Site
Coimbatore, Tamil Nadu, India
Novo Nordisk Investigational Site
Trichy, Tamil Nadu, India
Novo Nordisk Investigational Site
Kanpur, Uttar Pradesh, India
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.